Spyre Therapeutics (SYRE) Competitors $25.38 +0.12 (+0.48%) (As of 09:33 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends SYRE vs. KRYS, ACLX, ADMA, RARE, BHVN, APLS, IMVT, SRRK, RNA, and OGNShould you be buying Spyre Therapeutics stock or one of its competitors? The main competitors of Spyre Therapeutics include Krystal Biotech (KRYS), Arcellx (ACLX), ADMA Biologics (ADMA), Ultragenyx Pharmaceutical (RARE), Biohaven (BHVN), Apellis Pharmaceuticals (APLS), Immunovant (IMVT), Scholar Rock (SRRK), Avidity Biosciences (RNA), and Organon & Co. (OGN). These companies are all part of the "pharmaceutical products" industry. Spyre Therapeutics vs. Krystal Biotech Arcellx ADMA Biologics Ultragenyx Pharmaceutical Biohaven Apellis Pharmaceuticals Immunovant Scholar Rock Avidity Biosciences Organon & Co. Spyre Therapeutics (NASDAQ:SYRE) and Krystal Biotech (NASDAQ:KRYS) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation, media sentiment, analyst recommendations and community ranking. Do analysts rate SYRE or KRYS? Spyre Therapeutics currently has a consensus target price of $51.50, suggesting a potential upside of 102.92%. Krystal Biotech has a consensus target price of $206.67, suggesting a potential upside of 23.57%. Given Spyre Therapeutics' higher possible upside, research analysts plainly believe Spyre Therapeutics is more favorable than Krystal Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Spyre Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00Krystal Biotech 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.00 Is SYRE or KRYS more profitable? Krystal Biotech has a net margin of 21.68% compared to Spyre Therapeutics' net margin of 0.00%. Krystal Biotech's return on equity of 7.54% beat Spyre Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Spyre TherapeuticsN/A -210.01% -44.40% Krystal Biotech 21.68%7.54%6.97% Does the MarketBeat Community believe in SYRE or KRYS? Krystal Biotech received 273 more outperform votes than Spyre Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Spyre Therapeutics an outperform vote while only 67.37% of users gave Krystal Biotech an outperform vote. CompanyUnderperformOutperformSpyre TherapeuticsOutperform Votes16100.00% Underperform VotesNo VotesKrystal BiotechOutperform Votes28967.37% Underperform Votes14032.63% Does the media favor SYRE or KRYS? In the previous week, Krystal Biotech had 9 more articles in the media than Spyre Therapeutics. MarketBeat recorded 14 mentions for Krystal Biotech and 5 mentions for Spyre Therapeutics. Spyre Therapeutics' average media sentiment score of 0.57 beat Krystal Biotech's score of 0.33 indicating that Spyre Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spyre Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Krystal Biotech 4 Very Positive mention(s) 4 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has better earnings & valuation, SYRE or KRYS? Krystal Biotech has higher revenue and earnings than Spyre Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSpyre Therapeutics$890K1,466.65-$338.79M-$7.47-3.40Krystal Biotech$241.52M19.92$10.93M$1.7794.49 Do insiders & institutionals believe in SYRE or KRYS? 80.4% of Spyre Therapeutics shares are held by institutional investors. Comparatively, 86.3% of Krystal Biotech shares are held by institutional investors. 6.2% of Spyre Therapeutics shares are held by company insiders. Comparatively, 14.1% of Krystal Biotech shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has more risk & volatility, SYRE or KRYS? Spyre Therapeutics has a beta of 2.82, meaning that its share price is 182% more volatile than the S&P 500. Comparatively, Krystal Biotech has a beta of 0.8, meaning that its share price is 20% less volatile than the S&P 500. SummaryKrystal Biotech beats Spyre Therapeutics on 12 of the 18 factors compared between the two stocks. Ad Brownstone ResearchMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.Click here to watch this demo and decide for yourself. Get Spyre Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SYRE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SYRE vs. The Competition Export to ExcelMetricSpyre TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.31B$6.85B$5.15B$9.28BDividend YieldN/A3.06%4.81%4.06%P/E Ratio-3.4010.79135.4217.51Price / Sales1,466.65286.571,184.62142.21Price / CashN/A56.6540.4237.95Price / Book-115.365.404.894.94Net Income-$338.79M$152.04M$118.71M$225.59M7 Day Performance-4.01%-4.19%15.74%-1.07%1 Month Performance-11.48%2.70%15.70%7.23%1 Year Performance60.53%17.16%34.85%22.97% Spyre Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SYRESpyre Therapeutics1.9281 of 5 stars$25.38+0.5%$51.50+102.9%+63.0%$1.31B$890,000.00-3.40100KRYSKrystal Biotech4.3121 of 5 stars$167.61+2.4%$206.67+23.3%+46.0%$4.82B$50.70M92.45229Analyst ForecastACLXArcellx3.0444 of 5 stars$83.42-0.5%$105.93+27.0%+60.5%$4.51B$155.82M-118.03130ADMAADMA Biologics3.8605 of 5 stars$18.98+2.1%$21.25+12.0%+343.6%$4.49B$382.81M67.57530Short Interest ↓RAREUltragenyx Pharmaceutical4.5688 of 5 stars$45.40-0.8%$87.46+92.6%-2.2%$4.19B$434.25M-7.081,276BHVNBiohaven3.8327 of 5 stars$41.44+7.7%$63.00+52.0%+0.3%$4.19B$462.51M-4.48239Analyst ForecastAPLSApellis Pharmaceuticals4.721 of 5 stars$33.66+1.4%$49.94+48.4%-34.5%$4.19B$396.59M-16.35702Analyst DowngradeShort Interest ↓Positive NewsHigh Trading VolumeIMVTImmunovant1.4499 of 5 stars$27.63+5.1%$47.89+73.3%-34.7%$4.06BN/A-11.84120SRRKScholar Rock3.9591 of 5 stars$42.87+2.1%$40.43-5.7%+130.0%$4.01B$33.19M-18.35140Positive NewsRNAAvidity Biosciences2.5121 of 5 stars$33.39+2.8%$63.60+90.5%+278.5%$3.98B$10.12M-11.28190Gap DownOGNOrganon & Co.4.851 of 5 stars$14.58-4.7%$21.33+46.3%+12.9%$3.75B$6.26B2.9110,000 Related Companies and Tools Related Companies KRYS Competitors ACLX Competitors ADMA Competitors RARE Competitors BHVN Competitors APLS Competitors IMVT Competitors SRRK Competitors RNA Competitors OGN Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SYRE) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | Sponsored2025’s #1 Trump TradeAll the Energy You Need to Power Your Entire Life... Could Fit Inside This Single Soda Can. Three Companies...The Oxford Club | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredHealthcare Takes A Big Step Forward With The Help of A.I.To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still s...Wall Street Star | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored50-year Wall Street legend: “Sell this tech stock NOW”Something very strange is happening to U.S. stocks following President Trump's victory... And this could s...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spyre Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Spyre Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SYRE Stock Alerts